CompletedPhase 2

Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy

Sweden100 participantsStarted 2011-11

Plain-language summary

To evaluate if intravitreal Ozurdex can reduce the incidence of recurrent vitreous hemorrhage after primary pars plana vitrectomy (PPV) in patients with proliferative diabetic retinopathy (PDRP).

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with vitreous hemorrhage undergoing PPV for PDRP Exclusion Criteria: * Previous PPV * Vitreous hemorrhage of non-PDRP origin

What they're measuring

Reoperation

Timeframe: 12 months

Trial details

NCT IDNCT01478737

SponsorAnders Kvanta

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-04

View on ClinicalTrials.gov More Proliferative Diabetic Retinopathy trials